Quick Answer
Corvus Pharmaceuticals, Inc. reported Total Assets of $71.12 million for the year ending 2025.
- Corvus Pharmaceuticals, Inc. showed an increase of +3.2% in Total Assets from 2024 to 2025.
- This data is from Corvus Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on March 12, 2026.
- XBRL data for this metric is available from 2015 to 2025 (11 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2016: $157.22 million | Q2 2016: $156.92 million | Q3 2016: $149.76 million | Q1 2017: $127.10 million | Q2 2017: $115.49 million | Q3 2017: $104.79 million | Q1 2018: $148.69 million | Q2 2018: $137.92 million | Q3 2018: $127.22 million | Q1 2019: $112.31 million | Q2 2019: $103.12 million | Q3 2019: $92.47 million | Q1 2020: $73.80 million | Q2 2020: $64.18 million | Q3 2020: $55.86 million | Q1 2021: $109.24 million | Q2 2021: $109.39 million | Q3 2021: $119.32 million | Q1 2022: $101.29 million | Q2 2022: $92.54 million | Q3 2022: $80.35 million | Q1 2023: $58.20 million | Q2 2023: $58.04 million | Q3 2023: $51.94 million | Q1 2024: $40.08 million | Q2 2024: $64.56 million | Q3 2024: $58.82 million | Q1 2025: $59.44 million | Q2 2025: $89.46 million | Q3 2025: $80.47 million.
- Over the full 11 years of available data (2015 to 2025), Corvus Pharmaceuticals, Inc.'s Total Assets has declined by 27.8%.
- Historical annual values: Fiscal year 2025: $71.12 million | Fiscal year 2024: $68.91 million | Fiscal year 2023: $45.55 million | Fiscal year 2022: $68.24 million | Fiscal year 2021: $109.46 million | Fiscal year 2020: $85.53 million | Fiscal year 2019: $83.65 million | Fiscal year 2018: $118.23 million | Fiscal year 2017: $94.78 million | Fiscal year 2016: $140.15 million | Fiscal year 2015: $98.46 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: